Clearside Biomedical, Inc.

Clearside Biomedical, Inc.verified

CLSD

Price:

$0.85

Market Cap:

$64.47M

Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase 1/2a clinical trial; and CLS-301, an integrin inhibitor suspension for the treatment of diabetic macular edema and macular degeneration. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated i...[Read more]

Industry

Biotechnology

IPO Date

2016-06-02

Stock Exchange

NASDAQ

Ticker

CLSD

The Enterprise Value as of December 2024 (TTM) for Clearside Biomedical, Inc. (CLSD) is 51.36M

According to Clearside Biomedical, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 51.36M. This represents a change of -50.05% compared to the average of 102.82M of the last 4 quarters.

Clearside Biomedical, Inc. (CLSD) Historical Enterprise Value (quarterly & annually)

How has CLSD Enterprise Value performed in the past?

The mean historical Enterprise Value of Clearside Biomedical, Inc. over the last ten years is 90.07M. The current 51.36M Enterprise Value has changed 5.60% with respect to the historical average. Over the past ten years (40 quarters), CLSD's Enterprise Value was at its highest in in the September 2021 quarter at 332.39M. The Enterprise Value was at its lowest in in the June 2015 quarter at 0.

Quarterly (TTM)
Annual

Average

90.07M

Median

88.19M

Minimum

20.46M

Maximum

175.97M

Clearside Biomedical, Inc. (CLSD) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Clearside Biomedical, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 322.34%

Maximum Annual Enterprise Value = 175.97M

Minimum Annual Increase = -84.40%

Minimum Annual Enterprise Value = 20.46M

Quarterly (TTM)
Annual
YearEnterprise ValueChange
202386.40M322.34%
202220.46M-84.40%
2021131.09M16.92%
2020112.12M18.63%
201994.51M171.45%
201834.82M-80.21%
2017175.97M95.57%
201689.97M20.48%
201574.68M-7.48%
201480.72M-7.59%

Clearside Biomedical, Inc. (CLSD) Average Enterprise Value

How has CLSD Enterprise Value performed in the past?

The current Enterprise Value of Clearside Biomedical, Inc. (CLSD) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

3-year avg

79.31M

5-year avg

88.91M

10-year avg

90.07M

Clearside Biomedical, Inc. (CLSD) Enterprise Value vs. Peers

How is CLSD’s Enterprise Value compared to its peers?

Clearside Biomedical, Inc.’s Enterprise Value is less than POINT Biopharma Global Inc. (1.32B), less than ORIC Pharmaceuticals, Inc. (532.60M), greater than Lyra Therapeutics, Inc. (22.76M), greater than Inhibrx Biosciences, Inc. (15.40M), greater than ESSA Pharma Inc. (-31498128.00), greater than Sensei Biotherapeutics, Inc. (-3090841.00), greater than NextCure, Inc. (4.72M), less than Nuvation Bio Inc. (891.57M), greater than Graphite Bio, Inc. (-15007658.00), greater than Merrimack Pharmaceuticals, Inc. (-10189682.00), less than Gracell Biotechnologies Inc. (5.66B), less than Theseus Pharmaceuticals, Inc. (138.26M), less than Monte Rosa Therapeutics, Inc. (347.87M), less than Design Therapeutics, Inc. (327.21M), less than Erasca, Inc. (717.73M), greater than Eyenovia, Inc. (15.34M), less than Alpha Tau Medical Ltd. (222.41M), less than Ocular Therapeutix, Inc. (965.38M), less than Tenaya Therapeutics, Inc. (134.50M), less than Inozyme Pharma, Inc. (208.83M), less than Generation Bio Co. (143.26M), greater than Kronos Bio, Inc. (8.01M), less than C4 Therapeutics, Inc. (277.10M), less than Edgewise Therapeutics, Inc. (2.76B),

Build a custom stock screener for Clearside Biomedical, Inc. (CLSD) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Clearside Biomedical, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Clearside Biomedical, Inc. (CLSD) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Clearside Biomedical, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the Enterprise Value?

How can you use the Enterprise Value?

What is Clearside Biomedical, Inc.'s Enterprise Value?

What is the highest Enterprise Value for Clearside Biomedical, Inc. (CLSD)?

What is the 3-year average Enterprise Value for Clearside Biomedical, Inc. (CLSD)?

What is the 5-year average Enterprise Value for Clearside Biomedical, Inc. (CLSD)?

How does the current Enterprise Value for Clearside Biomedical, Inc. (CLSD) compare to its historical average?